Hence, the combination regimen of Bevacizumab and SHH002-hu1 provides an effective candidate for the clinical treatment of TNBC, especially PD-L1− TNBC and triple-negative operable primary invasive breast cancer. This evidence concerns the gene CD274 and invasive breast carcinoma.